Monthly Haemostatic Factor Variability in Women and Men

Overview

Journal Eur J Clin Invest

Publisher Wiley

Specialty General Medicine

Date 2014 Jan 3

PMID 24382103

Citations 2

Authors

Alison M Hill

Paul W Stewart

Mark K Fung

Penny M Kris-Etherton

Henry N Ginsberg

Russell P Tracy

Thomas A Pearson

Michael Lefevre

Roberta G Reed

Patricia J Elmer

Stephen Holleran

Abby G Ershow

Affiliations

Soon will be listed here.

Abstract

Background: Hormonal status influences haemostatic factors including fibrinogen, factor VII and plasminogen activator inhibitor (PAI-1), and concentrations differ among men, premenopausal and postmenopausal women. This study examines how phases of the menstrual cycle influence variability of fibrinogen, factor VII and PAI-1.

Design: We studied 103 subjects (39 premenopausal women, 18 postmenopausal women and 46 men) during three, randomized, 8-week energy- and nutrient-controlled experimental diets in the Dietary Effects on Lipids and Thrombogenic Activity (DELTA) Study. Fasting blood samples were collected weekly during the last 4 weeks of each diet period, and haemostatic factors were quantified. Two linear mixed-effects models were used for fibrinogen, factor VII and PAI-1: one to estimate and compare group-specific components of variance, and the other to estimate additional fixed effects representing cyclical functions of day of menstrual cycle in premenopausal women.

Results: Systematic cyclical variation with day of menstrual cycle was observed for fibrinogen (P < 0.0001), factor VII (P = 0.0012) and PAI-1 (P = 0.0024) in premenopausal women. However, the amplitude of cycling was small relative to the total magnitude of intra-individual variability. In addition, the intra-individual variance and corresponding coefficient of variation observed in premenopausal women did not differ from postmenopausal women and men.

Conclusions: The variability in haemostatic factors in premenopausal women is no greater than for postmenopausal women or men. Consequently, premenopausal women can be included in studies investigating haemostatic factor responses without controlling for stage of menstrual cycle.

Citing Articles

Correlation Between Blood Coagulation Profile and Viscosity: Clinical Laboratory Observational Study.

Nwose E, Bwititi P Med Sci (Basel). 2025; 13(1).

PMID: 39982245 PMC: 11843925. DOI: 10.3390/medsci13010020.

The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials.

Kris-Etherton P, Stewart P, Ginsberg H, Tracy R, Lefevre M, Elmer P J Nutr. 2020; 150(8):2089-2100.

PMID: 32492148 PMC: 7398773. DOI: 10.1093/jn/nxaa137.

Comparison of the effects of spinal epidural and general anesthesia on coagulation and fibrinolysis in laparoscopic cholecystectomy: a randomized controlled trial: VSJ Competition, 2 place.

Demiryas S, Donmez T, Erdem V, Erdem D, Hatipoglu E, Ferahman S Wideochir Inne Tech Maloinwazyjne. 2017; 12(3):330-340.

PMID: 29062459 PMC: 5649509. DOI: 10.5114/wiitm.2017.70249.

References

Lidegaard O, Milsom I, Geirsson R, Skjeldestad F . Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand. 2012; 91(7):769-78. DOI: 10.1111/j.1600-0412.2012.01444.x. View

Andersson O, Blomback M, Bremme K, Wramsby H . Prediction of changes in levels of haemostatic variables during natural menstrual cycle and ovarian hyperstimulation. Thromb Haemost. 1997; 77(5):901-4. View

Clauss A . [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematol. 1957; 17(4):237-46. DOI: 10.1159/000205234. View

Cushman M . Epidemiology and risk factors for venous thrombosis. Semin Hematol. 2007; 44(2):62-9. PMC: 2020806. DOI: 10.1053/j.seminhematol.2007.02.004. View

Ginsberg H, Dennis B, Elmer P, Ershow A, Lefevre M, Pearson T . Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol. 1998; 18(3):441-9. DOI: 10.1161/01.atv.18.3.441. View

Koh S, Prasad R, Fong Y . Hemostatic status and fibrinolytic response potential at different phases of the menstrual cycle. Clin Appl Thromb Hemost. 2005; 11(3):295-301. DOI: 10.1177/107602960501100308. View

Reed R, Stewart P, PEARSON T . Variation of lipids and lipoproteins in premenopausal women compared with men and postmenopausal women. DELTA (Dietary Effects on Lipoproteins and Thrombogenic Activity) Investigators. Metabolism. 2000; 49(9):1101-5. DOI: 10.1053/meta.2000.8603. View

Chung H, Rha S, Park J, Yoo N, Kim J, Roh J . Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients. Breast Cancer Res Treat. 1998; 49(1):41-50. DOI: 10.1023/a:1005997421733. View

Trigg D, Wood M, Kouides P, Kadir R . Hormonal influences on hemostasis in women. Semin Thromb Hemost. 2011; 37(1):77-86. DOI: 10.1055/s-0030-1270074. View

10.

Thogersen A, Jansson J, Boman K, Nilsson T, Weinehall L, Huhtasaari F . High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998; 98(21):2241-7. DOI: 10.1161/01.cir.98.21.2241. View

11.

Lefevre M, Ginsberg H, Kris-Etherton P, Elmer P, Stewart P, Ershow A . ApoE genotype does not predict lipid response to changes in dietary saturated fatty acids in a heterogeneous normolipidemic population. The DELTA Research Group. Dietary Effects on Lipoproteins and Thrombogenic Activity. Arterioscler Thromb Vasc Biol. 1997; 17(11):2914-23. DOI: 10.1161/01.atv.17.11.2914. View

12.

Juhan-Vague I, Pyke S, Alessi M, Jespersen J, Haverkate F, Thompson S . Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. Circulation. 1996; 94(9):2057-63. DOI: 10.1161/01.cir.94.9.2057. View

13.

Declerck P, Alessi M, Verstreken M, Kruithof E, Juhan-Vague I, Collen D . Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988; 71(1):220-5. View

14.

Knol H, Kemperman R, Kluin-Nelemans H, Mulder A, Meijer K . Haemostatic variables during normal menstrual cycle. A systematic review. Thromb Haemost. 2011; 107(1):22-9. DOI: 10.1160/TH11-07-0481. View

15.

Seligsohn U, Osterud B, Griffin J, RAPAPORT S . Evidence for the participation of both activated factor XII and activated factor IX in cold-promoted activation of factor VII. Thromb Res. 1978; 13(6):1049-56. DOI: 10.1016/0049-3848(78)90233-5. View

16.

Giardina E, Chen H, Sciacca R, Rabbani L . Dynamic variability of hemostatic and fibrinolytic factors in young women. J Clin Endocrinol Metab. 2004; 89(12):6179-84. DOI: 10.1210/jc.2004-0598. View

17.

Marckmann P, Sandstrom B, Jespersen J . The variability of and associations between measures of blood coagulation, fibrinolysis and blood lipids. Atherosclerosis. 1992; 96(2-3):235-44. DOI: 10.1016/0021-9150(92)90070-w. View

18.

Ginsberg H . New directions in dietary studies and heart disease: the National Heart, Lung and Blood Institute sponsored Multicenter Study of Diet Effects on Lipoproteins and Thrombogenic Activity. Adv Exp Med Biol. 1995; 369:241-7. DOI: 10.1007/978-1-4615-1957-7_23. View

19.

Kapiotis S, Jilma B, Pernerstorfer T, Stohlawetz P, Eichler H, Speiser W . Plasma levels of activated factor VII decrease during the menstrual cycle. Thromb Haemost. 1998; 80(4):588-91. View

20.

Borgfeldt C, Li C, Samsioe G . Low-dose oral combination of 17beta-estradiol and norethisterone acetate in postmenopausal women decreases factor VII, fibrinogen, antithrombin and plasminogen activator inhibitor-1. Climacteric. 2004; 7(1):78-85. DOI: 10.1080/13697130310001651508. View